Volume 20, Number 1—January 2014
Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan
|Outcome||No vaccination||Scenario C, 90% vaccine coverage, 2-y vaccination protection
|Avoided outcomes, undiscounted
|Home care episodes||2,675,456||1,544,202||747,494||2,390,646|
|Avoided costs, undiscounted, US $43 per vaccine dose
|Prevented in-hospital care||25.7||19.7||17.8||21.8|
|Prevented outpatient care||16.3||12.5||7.3||18.1|
|Avoided indirect costs||179.4||130.7||95.2||169.2|
|Total net costs in US$
|Incremental cost-effectiveness ratios, societal perspective
|Incremental cost-effectiveness ratios, health care perspective
|Threshold prices, 3% discounting
|Medical break-even price†||NA||$2.95||$2.15||$3.79|
*NA, not applicable.
†The price per vaccine dose at which the vaccinations costs are offset by cost saving generated from lower morbidity and mortality rates.
Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.